our Premium Content: News alerts, weekly reports and conference planners
Other names: BioNTech | BioNTech AG | BioNTech SE | Neon Therapeutics | Neon Therapeutics, Inc. | BioNTech US Inc. | BioNTech US Inc | BioNTech US | BioNTech Diagnostics GmbH | BioNTech Diagnostics | Neon Therapeutics Inc | Neon Therapeutics Inc. | Neon Therapeutics, Inc | Biopharmaceutical New Technologies (BioNTech) | Biopharmaceutical New Technologies
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
"Cerca Biotech GmbH...announced an asset purchase agreement with BioNTech Diagnostics AG...relating to MammaTyper®, a molecular diagnostics for breast cancer subtyping. Under the agreement, Cerca will acquire from BioNTech its rights and interest in MammaTyper® and the associated nucleic acid extraction kit RNXtract®. Cerca will be responsible for the development and commercialization of the products worldwide."